Molecure S.A. Logo

Molecure S.A.

Develops first-in-class small molecule drugs for oncology and inflammatory/fibrotic diseases.

MOC | WAR

Overview

Corporate Details

ISIN(s):
PLONCTH00011
LEI:
2594003L11V38ZCVKZ09
Country:
Poland
Address:
Warszawa Żwirki i Wigury 101, 02-089 Warszawa
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Molecure S.A. is a clinical-stage biotechnology company that discovers and develops first-in-class small molecule drugs. The company focuses on treating diseases with high unmet medical needs, primarily in oncology and inflammatory and fibrotic conditions. Leveraging its in-house medicinal chemistry and biology capabilities, Molecure targets novel and unexplored protein and mRNA targets through its proprietary discovery platform. Its business model involves advancing a diverse pipeline of drug candidates to the clinical stage before engaging in licensing agreements for late-stage development and commercialization. The company was formerly known as OncoArendi, changing its name in March 2022.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-27 07:11
Quarterly Report
Skonsolidowany raport Grupy Kapitałowej za III kwartał 2025 roku
Polish 2.6 MB
2025-10-22 19:50
Report Publication Announcement
Zmiana terminu publikacji raportu za III kwartał 2025 roku. - Content (PL)
Polish 917 bytes
2025-10-21 16:00
Declaration of Voting Results & Voting Rights Announcements
Wykaz akcjonariuszy posiadających co najmniej 5% liczby głosów na Nadzwyczajnym…
Polish 2.0 KB
2025-10-21 15:46
Post-Annual General Meeting Information
Treść powziętych uchwał
Polish 229.8 KB
2025-10-21 15:46
Post-Annual General Meeting Information
Treść uchwał podjętych przez Nadzwyczajne Walne Zgromadzenie w dniu 21 paździer…
Polish 686 bytes
2025-09-30 07:56
Audit Report / Information
Raport z przeglądu SSF 30.06.2025
Polish 236.4 KB
2025-09-30 07:56
Audit Report / Information
Raport z przeglądu JSF 30.06.2025
Polish 233.4 KB
2025-09-30 07:56
Management Discussion and Analysis
Sprawozdanie Zarządu z działalności Molecure S.A. 30.06.2025
Polish 1.5 MB
2025-09-30 07:56
Interim Report
Skonsolidowane Sprawozdanie Finansowe Molecure S.A. 30.06.2025
Polish 1.1 MB
2025-09-30 07:56
Interim Report
Jednostkowe Sprawozdanie Finansowe Molecure S.A. 30.06.2025
Polish 1.2 MB
2025-09-26 17:16
Regulatory News Service
Informacja o pozytywnej ocenie wniosku Spółki w ramach ścieżki "SMART" - Projek…
Polish 2.5 KB
2025-09-23 15:18
Pre-Annual General Meeting Information
Zaktualizowane projekty uchwał
Polish 225.0 KB
2025-09-23 15:18
Pre-Annual General Meeting Information
Aktualizacja Zarządu dotycząca projektu Uchwały Nadzwyczajnego Walnego Zgromadz…
Polish 4.9 KB
2025-09-22 20:37
Pre-Annual General Meeting Information
Załącznik - Projekty uchwał
Polish 227.6 KB
2025-09-22 20:37
Pre-Annual General Meeting Information
Projekty uchwał Nadzwyczajnego Walnego Zgromadzenia - Content (PL)
Polish 469 bytes

Automate Your Workflow. Get a real-time feed of all Molecure S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Molecure S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Molecure S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Resolute Holdings Management, Inc. Logo
Asset management firm acquiring and operationally enhancing companies for long-term growth.
United States of America
RHLD
Develops RNA aptamer therapeutics for ophthalmology, pain, fibrosis, and other unmet medical needs.
Japan
4591
Rise Consulting Group, Inc. Logo
Execution-focused consulting for strategy and digital transformation, specializing in JP-CN markets.
Japan
9168
ROQUEFORT THERAPEUTICS PLC Logo
Developing first-in-class, pre-clinical medicines for hard-to-treat cancers.
United Kingdom
ROQ
ROSS GROUP PLC Logo
A holding company in liquidation, formerly providing supply chain management & technology solutions.
United Kingdom
RGP
ROXX, Inc. Logo
HR tech platform connecting non-desk job seekers with full-time roles using AI and vetting tools.
Japan
241A
SAFTEC CO.,LTD. Logo
Rents and sells safety equipment for construction, from basic supplies to AI/IoT solutions.
Japan
7464
Salarius Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted protein therapies for cancer and viral diseases.
United States of America
SLRX
Saniona Logo
Develops ion channel medicines for rare neurological diseases and epilepsy.
Denmark
SANION
Santech Holdings Ltd Logo
A technology company developing innovative consumer and enterprise technology businesses.
United States of America
STEC

Talk to a Data Expert

Have a question? We'll get back to you promptly.